CA3008634A1 - Pharmaceutical compositions comprising phenylaminopyrimidine derivative - Google Patents
Pharmaceutical compositions comprising phenylaminopyrimidine derivative Download PDFInfo
- Publication number
- CA3008634A1 CA3008634A1 CA3008634A CA3008634A CA3008634A1 CA 3008634 A1 CA3008634 A1 CA 3008634A1 CA 3008634 A CA3008634 A CA 3008634A CA 3008634 A CA3008634 A CA 3008634A CA 3008634 A1 CA3008634 A1 CA 3008634A1
- Authority
- CA
- Canada
- Prior art keywords
- nrc
- formulation
- polymer
- solvent
- acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN6951CH2015 | 2015-12-18 | ||
| IN6951/CHE/2015 | 2015-12-18 | ||
| PCT/IN2016/050035 WO2017103941A1 (en) | 2015-12-18 | 2016-01-30 | Pharmaceutical compositions comprising phenylaminopyrimidine derivative |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3008634A1 true CA3008634A1 (en) | 2017-06-22 |
Family
ID=59055898
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3008634A Abandoned CA3008634A1 (en) | 2015-12-18 | 2016-01-30 | Pharmaceutical compositions comprising phenylaminopyrimidine derivative |
Country Status (33)
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI773657B (zh) | 2015-12-18 | 2022-08-11 | 美商亞德利克斯公司 | 作爲非全身ｔｇｒ５促效劑之經取代之4-苯基吡啶化合物 |
| US12084472B2 (en) | 2015-12-18 | 2024-09-10 | Ardelyx, Inc. | Substituted 4-phenyl pyridine compounds as non-systemic TGR5 agonists |
| CZ2017821A3 (cs) * | 2017-12-20 | 2019-07-03 | Zentiva, K.S. | Léková forma obsahující krystalický nilotinib |
| CN112118830B (zh) * | 2018-05-14 | 2023-11-10 | 比利时胶囊公司 | 高活性剂载量的固体剂型 |
| JP7368548B2 (ja) * | 2021-07-02 | 2023-10-24 | 昊運股▲フン▼有限公司 | 薬学的組成物及びその使用 |
| CN115583634B (zh) * | 2022-09-21 | 2023-06-06 | 广东工业大学 | 一种碳氮聚合物材料的制备方法及应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2002241268A (ja) * | 2000-12-11 | 2002-08-28 | Takeda Chem Ind Ltd | 水溶解性が改善された医薬組成物 |
| AP2470A (en) | 2004-09-09 | 2012-09-17 | Natco Pharma Ltd | Novel phenylaminopyrimidine derivatives as inhibitors of BCR-ABL kinase |
| US8067422B2 (en) | 2008-03-04 | 2011-11-29 | Natco Pharma Limited | Crystal form of phenylamino pyrimidine derivatives |
| WO2012002547A1 (ja) * | 2010-07-02 | 2012-01-05 | 富士化学工業株式会社 | ボセンタン固体分散体 |
| GB2488788B (en) | 2011-03-07 | 2013-07-10 | Natco Pharma Ltd | Oral formulation of phenylaminopyrymidine compound with enhanced bioavailability and pharmacological response |
| CN102836159B (zh) * | 2011-06-24 | 2014-12-10 | 南京圣和药业股份有限公司 | 达沙替尼分散体及其制备方法和其在片剂中的应用 |
| JP2017500343A (ja) * | 2013-12-20 | 2017-01-05 | フォスフォレックス，インコーポレーテッド | インジルビン固体分散体組成物 |
-
2016
- 2016-01-30 SG SG11201805142RA patent/SG11201805142RA/en unknown
- 2016-01-30 EP EP16875074.3A patent/EP3389633B1/en active Active
- 2016-01-30 GE GEAP201614833A patent/GEP20207176B/en unknown
- 2016-01-30 RS RS20211232A patent/RS62422B1/sr unknown
- 2016-01-30 US US16/062,320 patent/US10383872B2/en not_active Expired - Fee Related
- 2016-01-30 KR KR1020187020546A patent/KR20180102584A/ko not_active Ceased
- 2016-01-30 WO PCT/IN2016/050035 patent/WO2017103941A1/en not_active Ceased
- 2016-01-30 SM SM20210583T patent/SMT202100583T1/it unknown
- 2016-01-30 GE GEAP202014833A patent/GEAP202014833A/en unknown
- 2016-01-30 LT LTEPPCT/IN2016/050035T patent/LT3389633T/lt unknown
- 2016-01-30 DK DK16875074.3T patent/DK3389633T3/da active
- 2016-01-30 HU HUE16875074A patent/HUE056269T2/hu unknown
- 2016-01-30 MX MX2018007281A patent/MX374725B/es active IP Right Grant
- 2016-01-30 EA EA201891443A patent/EA036513B1/ru unknown
- 2016-01-30 CA CA3008634A patent/CA3008634A1/en not_active Abandoned
- 2016-01-30 PL PL16875074T patent/PL3389633T3/pl unknown
- 2016-01-30 MA MA44079A patent/MA44079B1/fr unknown
- 2016-01-30 UA UAA201806892A patent/UA122592C2/uk unknown
- 2016-01-30 AU AU2016373574A patent/AU2016373574B2/en not_active Expired - Fee Related
- 2016-01-30 HR HRP20211590TT patent/HRP20211590T1/hr unknown
- 2016-01-30 JP JP2018532262A patent/JP6896738B2/ja not_active Expired - Fee Related
- 2016-01-30 ES ES16875074T patent/ES2881883T3/es active Active
- 2016-01-30 BR BR112018012458A patent/BR112018012458A2/pt not_active IP Right Cessation
- 2016-01-30 CN CN201680079960.9A patent/CN108495620B/zh not_active Expired - Fee Related
- 2016-01-30 SI SI201631339T patent/SI3389633T1/sl unknown
- 2016-01-30 PT PT168750743T patent/PT3389633T/pt unknown
- 2016-01-30 GB GB1811142.7A patent/GB2564262A/en not_active Withdrawn
- 2016-01-30 HK HK18113869.1A patent/HK1254573A1/zh unknown
-
2018
- 2018-06-14 CL CL2018001590A patent/CL2018001590A1/es unknown
- 2018-06-17 IL IL260085A patent/IL260085B/en unknown
- 2018-06-18 PH PH12018501292A patent/PH12018501292A1/en unknown
- 2018-06-22 ZA ZA2018/04203A patent/ZA201804203B/en unknown
- 2018-07-09 CO CONC2018/0007112A patent/CO2018007112A2/es unknown
-
2020
- 2020-12-03 JP JP2020201322A patent/JP2021059551A/ja not_active Withdrawn
-
2021
- 2021-10-13 CY CY20211100881T patent/CY1124580T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2993251T3 (en) | Pharmaceutical compositions of nilotinib | |
| AU2016373574B2 (en) | Pharmaceutical compositions comprising phenylaminopyrimidine derivative | |
| JP2016505029A (ja) | 改良されたバイオアベイラビリティを有する薬学的組成物 | |
| WO2012116238A1 (en) | PHARMACEUTICAL FORMULATIONS OF ACETYL-11-KETO-β-BOSWELLIC ACID, DIINDOLYLMETHANE, AND CURCUMIN FOR PHARMACEUTICAL APPLICATIONS | |
| JP7112333B2 (ja) | 改善された薬物製剤 | |
| CN110603035A (zh) | 具有改善的水溶解度及生物利用率的组合物 | |
| KR102363727B1 (ko) | 생체이용률이 개선된 프란루카스트 함유 고형 제제의 조성물 및 그 제조방법 | |
| JP7378393B2 (ja) | 改善された薬物製剤 | |
| US20110311625A1 (en) | Solid dosage forms of fenofibrate | |
| EP2701689B1 (en) | Pharmaceutical compositions of raltegravir, methods of preparation and use thereof | |
| KR102707060B1 (ko) | 안정성 및 생체이용율이 개선된 올라파립 고체 분산체 조성물 | |
| KR101956586B1 (ko) | 약제학적 조성물 및 이의 제조방법 | |
| TW201805003A (zh) | Bcl-2抑制劑之醫藥固體分散物、其醫藥組合物及用於治療癌症之用途 | |
| JP2025526729A (ja) | ナポラフェニブを含む非晶質固体分散体 | |
| EA050832B1 (ru) | Твердая дисперсия, способ ее получения и твердый состав, который ее содержит | |
| WO2022029798A1 (en) | Pharmaceutical compositions comprising ribociclib | |
| HK40000762A (en) | Improved drug formulations | |
| WO2016087322A1 (de) | Feste, oral applizierbare pharmazeutische darreichungsformen mit schneller wirkstofffreisetzung | |
| NZ623628A (en) | Solid oral pharmaceutical formulations comprising amorphous (s)-methyl (1- ((4-(3-(5-chloro-2-fluoro-3-(methylsulfonamido)phenyl)-1-isopropy1-1h-pyrazo1-4-yl)pyrimidin-2-yl)amino)propan-2-yl)carbamate (compound a) | |
| NZ623628B2 (en) | Solid oral pharmaceutical formulations comprising amorphous (S)-methyl (1- ((4-(3-(5-chloro-2-fluoro-3-(methylsulfonamido)phenyl)-1-isopropy1-1H-pyrazo1-4-yl)pyrimidin-2-yl)amino)propan-2-yl)carbamate (Compound A) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20201203 |
|
| FZDE | Discontinued |
Effective date: 20230802 |